BioSpace News Archive

Providence Therapeutics Holdings Inc. (“Providence”), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced its mRNA drug discovery partnership with University Health Network (UHN), ranked first on a list of Canada’s top 40 research hospitals by Research Infosource Inc. and within one of the world’s top 5 hospitals for the fourth year in a row, as reported by Newsweek.

SciSparc Ltd. announced positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, which suggest that the Company’s proprietary SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in elderly population with Alzheimer disease and agitation.

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

CureALS, a pioneering nonprofit organization dedicated to eliminating ALS and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched.

International medical imaging IT and cybersecurity company Sectra reports that sales and operating profit for the fourth quarter and for the fiscal year exceeded previous records and recurring revenue increased.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that, with sponsorship and support from multiple physician specialty societies, the American Medical Association (“AMA”) has established three new Current Procedural Terminology (“CPT®’) Category 1 codes for MRI-Monitored Transurethral Ultrasound Ablation (“TULSA”) of prostate tissue, performed using Profound’s TULSA-PRO® system.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT.

The Board of Directors of Masimo Corporation announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management.

Promontory Therapeutics Inc. announces preliminary data from a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs), specifically thymoma and thymic carcinoma.